Abstracts
Guidance on the choice of data sources for cost weights in cost-effectiveness analyses in the literature is scarce with few empirical examples of cost weights derived from different approaches. OBJECTIVES: This paper describes the large differences that can be found in cost weights derived from different data sources and analytic approaches. We highlight the implications of the choice of costing data source and the magnitude of error that could be introduced by assuming data parity in direct comparisons of different studies.
Though our examples focus on HIV disease treatment, the issues we explore are generic to cost estimation for all conditions. METHODS: We compared annual HIV disease treatment cost weights from two data sets, the HIV Cost and Services Utilization Study (HCSUS) survey and South Carolina Medicaid data. Cost weights for hospital and nursing home stays and emergency room and physician visits were included in the analyses. RESULTS: The cost weights for Medicaid patients with AIDS were $15,033 in HCSUS and $10,281 in SC Medicaid data. Within the HCSUS data set, cost weights also varied greatly depending on whether the patient was covered by Medicaid ($15,033), Medicare ($8,487), private ($4,200) , or other public insurance ($19,347) . Further analysis of the HCSUS data found that the mean cost estimates for patients were larger when viral load (VL) data was missing ($8,413) than when it was included ($5,362). This difference was especially pronounced at higher CD4 cell count ranges. For example, the mean cost for patients with CD4 200-499 was $3,829 when VL was reported and $6,458 when it was missing, a difference of 67%. CONCLUSION: As this research illustrates, there may be large differences in cost weights that are derived from different data sources and analytic approaches. Accordingly, they should be given careful consideration when determining the external validity of economic studies.
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SATISFACTION WITH SMOKING CESSATION TREATMENTS-A SYSTEMATIC REVIEW OF THE DIMENSIONS
Holdford DA Virginia Commonwealth University, Richmond, VA, USA A major weakness of the literature on treatment satisfaction is the lack of rigor in the development of satisfaction measures. Part of this problem lies in the absence of an accepted conceptual model for treatment satisfaction. OBJECTIVES: This paper presents a conceptual model for treatment satisfaction and uses it to identify the underlying dimensions associated with smoking cessation treatments. METHODS: A systematic literature review of databases including MEDLINE, ABI-INFORM, Current Contents, and IPA was conducted. Key words used for the literature search included drug, patient, smoking, physician, pharmacist, placebo effect, and treatment satisfaction. Articles included in the review focused on drug and provider attributes shown in the literature to be significantly associated with overall perceptions of treatment experiences. Treatment satisfaction attributes involving high levels of patient-provider contact were emphasized due to their relevance to smoking cessation treatments. RESULTS: A conceptual model for treatment satisfaction, based upon the review, was considered to consist of a patient's assessment of salient aspects of the process and outcome of treatment experiences. Since treatment experiences often contain the administration of both products and services, the conceptual model was considered to consist of both product and service attributes. Support was found in the literature for this conceptualization since evidence showed that both product and service attributes have significant impact on overall evaluations of treatment experiences. Product-related attributes significantly impacting overall treatment satisfaction were categorized under four of the product quality dimensions defined by Garvin (1984) The Institute of Medicine Report on Patient Safety requests a 50% reduction of adverse events. This however, poses a challenge from a measurement perspective. Incidence estimates of adverse events have traditionally been based on medical case review, which is exhaustive and costly. Furthermore, the reliability of this method has been challenged. Recent studies have applied information technology to screen for adverse drug events (ADEs) in order to replace chart review. OBJECTIVE: To explore the extent to which automated health care data screens can be used to measure the incidence of in-hospital ADEs. METHODS: Systematic literature review. Keyword search of MEDLINE (1980 MEDLINE ( -2001 electronic database and hand search. Included studies had to describe specific screens that were applied to clinical or administrative databases to detect in-hospital ADEs. They also had to
